Press release
Varicella Zoster Infection Treatment Market to Witness Exponential Growth by 2027 | Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc
Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled “Varicella Zoster Infection Treatment Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027.” Varicella zoster infection comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a highly contagious infection with an incubation period of 10–21 days, most commonly 14–16 days, after which characteristic rashes appear. Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6466
On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population. Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications. In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.
For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc., and Dr. Reddy’s Laboratories Ltd., among others.
According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.
Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market
Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well. These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.
Request customized copy of report @ https://www.futuremarketinsights.com/customization-available/rep-gb-6466
Natural Products to Challenge Market Growth
Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.
About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.
Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Blog: http://www.marketresearchblog.org/
FMI Blog: https://www.fmiblog.com/
Web: https://www.futuremarketinsights.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Varicella Zoster Infection Treatment Market to Witness Exponential Growth by 2027 | Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc here
News-ID: 1573068 • Views: …
More Releases from Future Market Insights

Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
The Anesthesia Equipment Market is witnessing robust growth, with its value estimated at USD 9.3 billion in 2025 and projected to nearly double to USD 18.2 billion by 2035. This growth trajectory represents a compound annual growth rate of 7.0%, driven by increasing surgical volumes, rising prevalence of chronic respiratory and cardiovascular disorders, and ongoing expansion of healthcare infrastructure. The market is undergoing transformative change, as both established manufacturers and…

Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
The intravascular ultrasound (IVUS) systems market is on track to record consistent growth over the next decade. Valued at USD 893.7 million in 2025, the market is expected to expand to USD 1455.7 million by 2035, reflecting a compound annual growth rate of 5.0%. With cardiovascular disease remaining one of the leading causes of mortality globally, the demand for advanced intravascular imaging technologies is escalating. IVUS systems, which provide real-time…

Electric Power Sports Market to Reach USD 18.5 Billion by 2035
The global Electric Power Sports Market is on a fast track to transformation, as consumers, manufacturers, and policymakers align on one powerful goal: sustainable, high-performance recreational experiences. Valued at USD 10.3 billion in 2025, the market is projected to expand to USD 18.5 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.0%.
This momentum is set to generate an absolute dollar opportunity of USD 8.2 billion over…

Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovatio …
The global hair straightener market is entering a transformative growth phase, as industry leaders and emerging brands alike innovate to meet rising consumer demand for advanced hair styling solutions. Valued at USD 7.1 billion in 2025, the market is projected to reach USD 12.4 billion by 2035, registering a compound annual growth rate (CAGR) of 5.7% over the forecast period.
Between 2025 and 2030, the market is set to rise steadily…
More Releases for Varicella
Varicella Attenuated Live Vaccination Market Size Analysis by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Varicella Attenuated Live Vaccination market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The varicella attenuated live vaccination market is experiencing steady growth due to rising awareness about the importance of immunization against varicella-zoster virus (chickenpox).…
Global Live Attenuated Varicella Vaccine Market - Opportunities & Forecasts, 202 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global live attenuated varicella vaccine market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Varicella Live Vaccine Market to Witness Astonishing Growth by 2029
Varicella live vaccine market is anticipated to grow at a significant CAGR during the forecast period. The zoster virus is also known as human alphaherpesvirus 3 which is responsible for causing chickenpox and herpes zoster in the human body. Since the infection which is caused by these viruses is preventable by using vaccines specially formulated to provide immunity against the virus; the market is anticipated to grow substantially in the…
Varicella Live Vaccine Market to Reach $4,222 Million by 2026
Varicella live vaccine market was valued at $2.71 billion in 2018, and is expected to reach $4.22 billion by 2026, registering a CAGR of 5.7% from 2019 to 2026.
Viral infections can be prevented by immunization and therefore, immunization is crucial. Varicella zoster is a virus that causes diseases such as chicken pox and herpes zoster. However, these infectious diseases can be prevented by the use of varicella live vaccines. Varicella…
Varicella Live Vaccine Market Analysis with COVID-19 Effects
According to the report, the varicella live vaccine market was estimated at $2.71 billion in 2018 and is expected to hit $4.22 billion by 2026, registering a CAGR of 5.7% during the study period. The report offers a detailed analysis of the top winning strategies, top investment pockets, drivers & opportunities, market size & estimations, competitive landscape, and wavering market trends.
Increase in immunization programs across the globe, the surge in…
Varicella Live Vaccine Market Expected to Reach $4,222 Million by 2026
According to a new report published by Allied Market Research, titled,"Varicella Live Vaccine Market by Product, Application, and Provider: Global Opportunity Analysis and Industry Forecast, 2018-2026," the global varicella live vaccine market was valued at $2.71 billion in 2018, and is expected to reach $4.22 billion by 2026, registering a CAGR of 5.7% from 2019 to 2026.
Viral infections can be prevented by immunization and therefore, immunization is crucial. Varicella zoster…